Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/DAIICHI-SANKYO-CO-LTD-6498062/news/Daiichi-Sankyo-Two-Phase-3-Trials-of-Datopotamab-Deruxtecan-Plus-Durvalumab-Initiated-in-Patients-45590174/?utm_source=whatsapp&utm_medium=social&utm_campaign=share